Literature DB >> 4840438

Susceptibility of pathogenic actinomycetes to antimicrobial compounds.

P I Lerner.   

Abstract

Current interest in antimicrobial susceptibility testing of anaerobic pathogens and recent recognition that actinomycetes other than Actinomyces israelii may cause actinomycosis in man prompted this in vitro survey of 74 strains of actinomycetes, representing seven species. Minimum inhibitory concentrations (MICs) for 24 antimicrobials were determined by inhibition of gross colonial enlargement in semisolid antibiotic agar after incubation at 37 C for 48 h under anaerobic conditions. Erythromycin and rifampin were the most active drugs in vitro (MICs of 0.008 to 0.25 mug/ml), although a small number of non-israelii strains were conspicuously more resistant to the latter (MICs >0.5 mug/ml). Penicillin G, cephaloridine, minocycline, and clindamycin were also very active in vitro (MICs of 0.03 to 1.0 mug/ml); for a few non-israelii strains the MICs of clindamycin were 2.0 to 8.0 mug/ml. MICs of cephalothin, ampicillin, lincomycin, tetracycline, doxycycline, and chloramphenicol were well within a therapeutic range for all strains of A. israelii and most other species, although the MIC of lincomycin against a few non-israelii strains and of tetracycline and doxycycline against the majority of these strains was 2.0 to 8.0 mug/ml. Oxacillin, dicloxacillin, and cephalexin were less active in vitro, particularly against strains other than A. israelii. Most non-israelii species were not suppressed by 125 mug of metronidazole per ml, which concentration inhibited all strains of A. israelii; otherwise, there were no antimicrobial susceptibility differences among the species tested. Aminoglycoside activity was negligible.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4840438      PMCID: PMC428965          DOI: 10.1128/AAC.5.3.302

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  IDENTIFICATION OF SPECIES OF ACTINOMYCES.

Authors:  L K GEORG; G W ROBERTSTAD; S A BRINKMAN
Journal:  J Bacteriol       Date:  1964-08       Impact factor: 3.490

2.  SENSITIVITIES OF COLONIES AND SUSPENSIONS OF ACTINOMYCES ISRAELII TO PENICILLINS, TETRACYCLINES, AND ERYTHROMYCIN.

Authors:  G C BLAKE
Journal:  Br Med J       Date:  1964-01-18

3.  A NEW PATHOGENIC ANAEROBIC ACTINOYCES SPECIES.

Authors:  L K GEORG; G W ROBERTSTAD; S A BRINKMAN; M D HICKLIN
Journal:  J Infect Dis       Date:  1965-02       Impact factor: 5.226

4.  Actinomycosis and nocardiosis. A review of basic differences in therapy.

Authors:  J W PEABODY; J H SEABURY
Journal:  Am J Med       Date:  1960-01       Impact factor: 4.965

5.  Erythromycin in the treatment of actinomycosis.

Authors:  W E HERRELL; A BALOWS; J S DAILEY
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1955-09

6.  Actinomycosis of the lung; aetiology, diagnosis and chemotherapy.

Authors:  L P GARROD
Journal:  Tubercle       Date:  1952-09

7.  SENSITIVITY CHANGES OF ACTINOMYCES BOVIS TO PENICILLIN AND STREPTOMYCIN.

Authors:  A Boand; M Novak
Journal:  J Bacteriol       Date:  1949-05       Impact factor: 3.490

8.  The effect of aureomycin and penicillin on experimental actinomycosis infections in mice.

Authors:  R S GEISTER; E MEYER
Journal:  J Lab Clin Med       Date:  1951-07

9.  Clindamycin in the treatment of serious anaerobic infections.

Authors:  R J Fass; J F Scholand; G R Hodges; S Saslaw
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

10.  Primary pulmonary botryomycosis.

Authors:  W A Speir; J W Mitchener; R F Galloway
Journal:  Chest       Date:  1971-07       Impact factor: 9.410

View more
  14 in total

1.  Minimal inhibitory concentrations of various antimicrobial agents for human oral anaerobic bacteria.

Authors:  P J Baker; J Slots; R J Genco; R T Evans
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

2.  Susceptibility of 40 lactobacilli to six antimicrobial agents with broad gram-positive anaerobic spectra.

Authors:  A S Bayer; A W Chow; N Concepcion; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

3.  Tubo-ovarian Actinomycosis and the Use of Intrauterine Devices.

Authors:  R McLeod; S Smith; T E Poore; J L Lindsey; J S Remington
Journal:  West J Med       Date:  1980-06

4.  Actinomyces naeslundii as an agent of pelvic actinomycosis in the presence of an intrauterine device.

Authors:  W Bonnez; G Lattimer; N A Mohanraj; T H Johnson
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

5.  Lacrimal canaliculitis due to Arachnia (Actinomyces) propionica.

Authors:  D V Seal; J McGill; D Flanagan; B Purrier
Journal:  Br J Ophthalmol       Date:  1981-01       Impact factor: 4.638

6.  Nonsporing, anaerobic, gram-positive rods in saliva and the gingival crevice of humans.

Authors:  B Sanyal; C Russell
Journal:  Appl Environ Microbiol       Date:  1978-04       Impact factor: 4.792

7.  In vitro activity of gentamicin and minocycline alone and in combination against bacteria associated with intra-abdominal sepsis.

Authors:  R J Fass; D E Ruiz; R B Prior; R L Perkins
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

8.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

9.  New medium for isolation of Actinomyces viscosus and Actinomyces naeslundii from dental plaque.

Authors:  K S Kornman; W J Loesche
Journal:  J Clin Microbiol       Date:  1978-06       Impact factor: 5.948

10.  Thoracic vertebral actinomycosis: Actinomyces israelii and Fusobacterium nucleatum.

Authors:  Hitoshi Honda; Matthew J Bankowski; Eric H N Kajioka; Nalurporn Chokrungvaranon; Wesley Kim; Scott T Gallacher
Journal:  J Clin Microbiol       Date:  2008-03-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.